Development of pharmacokinetic simulator for adrenaline infusion

Pharmacokinetic analysis of adrenaline infusion for hypotension during general anesthesia with remimazolam - ADRAZOLAM trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031230653

Enrollment

Registered

2024-02-27

Start date

2024-02-27

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left ventricular dysfunction, Aortic/Mitral valve stenosis, Aortic/Mitral valve regurgitation cardiac disease, circulatory depression

Interventions

Blood specimen collection before and during general anesthesia

D001800

blood specimen collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Moderate or severe aortic/mitral valve regurgitation (2) Moderate or severe aortic/mitral valve stenosis (3) Left ventricular ejection fraction <=50%

Exclusion criteria

Exclusion criteria: Disease, condition, and physical status that affect adrenaline metabolism. (1) Off pump CABG (2) Arrhythmia requiring care (3) Patients who are administered with catecholamine (4) Patients under mechanical ventilation (5) Unruptured cerebral aneurysm of surgical indication (6) Allergy or contradiction for investigative drugs (7) Dialysis patients (8) Hepatic dysfunction (Child-Pugh grade C) (9) One lung ventilation (10) Height=30 kg/m2 (12) Patients administered with anti-psychotic or -depressant drug (13) Patients administered with monoamine oxidase inhibitor (14) Patients administered with steroids (15) Hyperthyroidism (16) Patients considered inappropriate for trial

Design outcomes

Primary

Measure	Time frame
serum adrenaline concentration	—

Secondary

Measure	Time frame
hypotensive events	—

Contacts

Public ContactMakoto Sasaki

Department of Anesthesiology and Critical Care Medicine, Yokohama City University

sasakiis@yokohama-cu.ac.jp+81-457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026